Cor Vasa 2010, 52(Suppl.):15-20 | DOI: 10.33678/cor.2010.198

Measuring of platelet activity and efficacy of antiplatelet therapy

Pavel Osmančík*, Petra Paulů, Petr Toušek, František Bednář, Zuzana Moťovská, Petr Widimský
III. interní-kardiologická klinika, Kardiocentrum, Fakultní nemocnice Královské Vinohrady a 3. lékařská fakulta Univerzity Karlovy, Praha, Česká republika

The aim of this paper is an overview of current options for measuring platelet activity and efficacy of antiplatelet therapy. The second part of the paper offers examples based on the authors' own experience. Particular attention is given to measurement of the effect of ADP antagonists.

Keywords: Platelets; Aspirin; Clopidogrel; Resistance

Published: December 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Osmančík P, Paulů P, Toušek P, Bednář F, Moťovská Z, Widimský P. Measuring of platelet activity and efficacy of antiplatelet therapy. Cor Vasa. 2010;52(Suppl.):15-20. doi: 10.33678/cor.2010.198.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. Go to original source... Go to PubMed...
    2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-1339.
    3. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929. Go to original source...
    4. Moťovská Z, Šujanová Z, Wimmerová S, et al. Comparison of cationic propyl gallate and adenosine diphosphate for the measurement of aspirin effectivity with optical aggregometry. Transl Res 2007;150:246-252. Go to original source... Go to PubMed...
    5. Osmančík PP, Bednář F, Mocíková H. Glycemia, triglycerides and disease severity are best associated with higher platelet activity in patients with stable coronary artery disease. J Thromb Thrombolysis 2007;24: 105-107. Go to original source... Go to PubMed...
    6. Bednář F, Osmančík P, Vaněk T, et al. Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET). J Thorac Cardiovasc Surg 2008;136:1054-1060. Go to original source... Go to PubMed...
    7. Osmančík PP, Bednář F, Mocíková H, et al. The comparison of platelet activity between patients with patent vs. occluded coronary artery bypass grafts. Thromb Res 2007;120:523-529. Go to original source... Go to PubMed...
    8. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175. Go to original source... Go to PubMed...
    9. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549. Go to original source... Go to PubMed...
    10. Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541-1547. Go to original source... Go to PubMed...
    11. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251. Go to original source... Go to PubMed...
    12. Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657-666. Go to original source... Go to PubMed...
    13. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000. Go to original source... Go to PubMed...
    14. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-242. Go to original source... Go to PubMed...
    15. Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007;98:1329-1334. Go to original source... Go to PubMed...
    16. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630-1636. Go to original source... Go to PubMed...
    17. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-1411. Go to original source... Go to PubMed...
    18. Moťovská Z, Widimský P, Petr R, et al. Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. Int J Cardiol 2009 Feb 14. [Epub ahead of print] Go to original source...
    19. Osmančík P, Jirmář R, Hulíková K, et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 2010;75: 158-166. Go to original source... Go to PubMed...
    20. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27:647-654. Go to original source... Go to PubMed...
    21. Cuisset T, Frere C, Quilici J, et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 2009;123:597-603. Go to original source... Go to PubMed...
    22. Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003;59:21-25. Go to original source... Go to PubMed...
    23. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360: 363-375. Go to original source... Go to PubMed...
    24. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362. Go to original source... Go to PubMed...
    25. http://clinicaltrials.gov/ct2/show/NCT00638794.
    26. http://clinicaltrials.gov/ct2/show/NCT00645918.
    27. Baker WL, White CM. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Am J Cardiovasc Drugs 2009;9:213-229. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes